Xaliproden SR 57746, SR 57746A, xaliproden hydrochloride, xaliprodene

Drugs in R and D

Volumn 4, Issue 6, 2003, Pages 386-388

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; BUSPIRONE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; NERVE GROWTH FACTOR; NEUROTRANSMITTER RECEPTOR; ORPHAN DRUG; SEROTONIN 1A AGONIST; SEROTONIN RECEPTOR; SR 57746 A; UNCLASSIFIED DRUG; XALIPRODEN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CANADA; CLINICAL TRIAL; DOSE RESPONSE; DRUG DESIGN; DRUG MECHANISM; DRUG SAFETY; EUROPE; HUMAN; JAPAN; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT INDICATION; UNITED STATES;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CLINICAL TRIALS; HUMANS; NAPHTHALENES; ORPHAN DRUG PRODUCTION; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS;

EID: 0242521526     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200304060-00014     Document Type: Article

References (6)

1. Doppler V, Lacomblez L, Bensimon G. Short term safety controlled trial of SR 57746A in amyotrophic lateral sclerosis. Methods and Findings in Experimental and Clinical Pharmacology 18 (Suppl. B): 205, 1996
2. Lacomblez L, Doppler V, Bensimon G. Safety and efficacy controlled trial of SR 57746A in amyotrophic lateral sclerosis. Methods and Findings in Experimental and Clinical Pharmacology 18 (Suppl. B): 206, 1996
3. Bachy A, Steinberg R, Santucci V, et al. Biochemical and electrophysiological properties of SR 57746A, a new, potent 5-HT1A receptor agonist. Fundamental and Clinical Pharmacology 7: 487-497, No. 9, 1993
4. Fournier J, Gauthier T, Keane PE. Neurotrophic effects of SR 57746A, a new non-peptide compound: in vitro studies. British Journal of Pharmacology 106 (Suppl.): 120P, Jul 1992
5. Roux S, Hubert I, Wettstein JG, et al. Facilitating effects of SR 57746A on short-term memory in an operant delayed alternation task in aged rats. Drug Development Research 35: 83-93, Jun 1995
6. Brooks BR, Sanjak M, Belden DS, et al. Delayed early loss of arm computerized isometric muscle strength (CIMS) in amyotrophic lateral sclerosis (ALS): a randomized, placebo-controlled ancillary study to the phase 3 clinical trials of SR57746A-xaliproden in patients treated and not treated witrh riluzole, conducted by the SR57746A-Xaliproden International ALS Study Group. Neurology 56 (Suppl. 3): 156, 2001